DRONTAL PLUS TASTE TABS

Manufacturer
Elanco US Inc.
Effective date
2026-03-03
Label type
PRESCRIPTION ANIMAL DRUG LABEL
Version
8
Source
full-release
Hydrated at
2026-06-01 02:46:34

Label at a glance#

ProductDRONTAL PLUS TASTE TABS
Active ingredientPRAZIQUANTEL, PYRANTEL PAMOATE, FEBANTEL
Label structure17 sections

Dosage and administration

  DOSAGE: The presence of parasites should be confirmed by laboratory fecal examination. Weigh the animal before treatment. Administer the proper dosage as specified in the following table as a single oral treatment. DRONTAL PLUS TASTE TABS TABLETS DOSAGE CHARTS *NOT FOR USE IN PUPPIES LESS THAN 3 WEEKS OF AGE OR DOGS WEIGHING LESS THAN 2 LBS. for Puppies and Small Dogs* (2 - 25 lbs.) for Medium Sized Dogs (26 - 6...

Storage and handling

Drontal Plus Taste Tabs Tablets should be stored at or below 77 °F (25 °C). Un-blistered whole or partial tablets should be stored in a tightly sealed container.

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

PA104396X

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

DESCRIPTION:

DESCRIPTION SECTION

Drontal Plus Taste Tabs (praziquantel/pyrantel pamoate/febantel) Broad Spectrum Chewable Anthelmintic Tablets for Dogs are available in three tablet sizes. Each size is scored for convenient oral administration.

Each Drontal Plus Taste Tabs Tablet for Puppies and Small Dogs contains 22.7 mg praziquantel, 22.7 mg pyrantel base as pyrantel pamoate and 113.4 mg febantel.

Each Drontal Plus Taste Tabs Tablet for Medium Sized Dogs contains 68.0 mg praziquantel, 68.0 mg pyrantel base as pyrantel pamoate and 340.2 mg febantel.

Each Drontal Plus Taste Tabs Tablet for Large Dogs contains 136.0 mg praziquantel, 136.0 mg pyrantel base as pyrantel pamoate, and 680.4 mg febantel.

ACTION:

SPL UNCLASSIFIED SECTION

Drontal Plus Taste Tabs Tablets contain three active ingredients having different modes of action and spectra of activity. Praziquantel is active against cestodes (tapeworms). Praziquantel is absorbed, metabolized in the liver and excreted in the bile. Upon entering the digestive tract from the bile, cestocidal activity is exhibited.1 Following exposure to praziquantel, the tapeworm loses its ability to resist digestion by the mammalian host. Because of this, whole tapeworms, including the scolices, are very rarely passed after administration of praziquantel. In many instances only disintegrated and partially digested pieces of tapeworms will be seen in the stool. The majority of tapeworms are digested and are not found in the feces.

Pyrantel pamoate is active against hookworms and ascarids. Pyrantel pamoate acts on the cholinergic receptors of the nematode resulting in spastic paralysis. Peristaltic action of the intestinal tract then eliminates the parasite.2

Febantel is active against nematode parasites including whipworms. Febantel is rapidly absorbed and metabolized in the animal. Available information suggests that the parasite's energy metabolism is blocked, leading to energy exchange breakdown and inhibited glucose uptake.

Laboratory efficacy and clinical studies conducted with Drontal Plus Anthelmintic Tablets demonstrate that each of the three active ingredients act independently without interference. The combined tablet formulation provides a wide spectrum of activity against the indicated species of intestinal helminths.

INDICATIONS:

INDICATIONS & USAGE SECTION

Drontal Plus (praziquantel/pyrantel pamoate/febantel) Taste Tabs Broad Spectrum Chewable Anthelmintic Tablets are indicated for removal of Tapeworms (Dipylidium caninum, Taenia pisiformis, Echinococcus granulosus, and removal and control of Echinococcus multilocularis) and for removal of Hookworms (Ancylostoma caninum, Uncinaria stenocephala), Ascarids (Toxocara canis, Toxascaris leonina), and Whipworms (Trichuris vulpis) in dogs.

CONTRAINDICATIONS:

CONTRAINDICATIONS SECTION

DO NOT USE IN PREGNANT ANIMALS. Dogs treated with elevated levels (6 consecutive days with 3 times the labeled dosage rate) of the combination of febantel and praziquantel in early pregnancy demonstrated an increased incidence of abortion and fetal abnormalities.8 The effects of Drontal Plus Anthelmintic Tablets on pregnant animals have not been determined.

There are no known contraindications against the use of praziquantel or pyrantel pamoate in dogs.

PRECAUTIONS:

PRECAUTIONS SECTION

Strict hygienic precautions should be taken when handling dogs or feces suspected of harboring E. multilocularis. Infected dogs treated for the first time with Drontal Plus Taste Tabs Tablets and dogs treated at intervals greater than 28 days may shed eggs in the feces after treatment. The animal should be held in the clinic during this interval and all feces should be incinerated or autoclaved. If these procedures are not possible, the eggs can be destroyed by soaking the feces in a sodium hypochlorite (bleach) solution of 3.75% or greater.7 All areas where the animal was maintained or in contact with should be thoroughly cleaned with sodium hypochlorite and allowed to dry completely before reuse.

WARNING:

WARNINGS SECTION

KEEP OUT OF REACH OF CHILDREN.

USE DIRECTIONS

DOSAGE & ADMINISTRATION SECTION

 

SPL UNCLASSIFIED SECTION

DOSAGE: The presence of parasites should be confirmed by laboratory fecal examination. Weigh the animal before treatment. Administer the proper dosage as specified in the following table as a single oral treatment.

DRONTAL PLUS TASTE TABS TABLETS DOSAGE CHARTS
*NOT FOR USE IN PUPPIES LESS THAN 3 WEEKS OF AGE OR DOGS WEIGHING LESS THAN 2 LBS.

for Puppies and
Small Dogs*
(2 - 25 lbs.)

for Medium Sized
Dogs
(26 - 60 lbs.)

for Large
Dogs
(45 lbs. and greater)

Body Wt.
(lbs.)

No. of
Tablets

Body Wt.
(lbs.)

No. of
Tablets

Body Wt.
(lbs.)

No. of
Tablets

2 - 4

0.5

26 - 30

1.0

45- 60

1.0

5 - 7

1.0

31 - 44

1.5

61 - 90

1.5

8 - 12

1.5

45 - 60

2.0

91 - 120

2.0

13 - 18

2.0

19 - 25

2.5

SPL UNCLASSIFIED SECTION

ADMINISTRATION: Most dogs find Drontal Plus Taste Tabs Tablets palatable. The tablets may be offered to the dog by hand. Alternatively tablets may be given directly by mouth or offered in a small amount of food. Fasting is neither necessary nor recommended prior to or after treatment.

SPL UNCLASSIFIED SECTION

RETREATMENT: For those animals living where reinfections are likely to occur, clients should be instructed in the steps to optimize prevention; otherwise, retreatment may be necessary. This is true in cases of Dipylidium caninum where reinfection is almost certain to occur if fleas are not removed from the animal and its environment. In addition, for control of Echinococcus multilocularis, a program of regular treatment every 21 to 26 days may be indicated (see E. multilocularis section below).

SPL UNCLASSIFIED SECTION

ECHINOCOCCUS MULTILOCULARIS: Echinococcus multilocularis is a tapeworm species usually found in wild canids, including foxes, coyotes and wolves. The parasite has also been identified in domestic dogs and cats and is potentially a serious public health concern because it may infect humans.

The life cycle of the parasite is based on a predator-prey relationship as depicted.

Figure
Figure

The adult tapeworm is small (1-4mm) and resides in the intestinal tract of the definitive host (wild or domestic canids). Eggs from the adult tapeworm are shed in the feces. Rodents such as mice and voles serve as the intermediate host. Eggs ingested by rodents develop in the liver, lungs and other organs to form multilocular cysts. The life cycle is completed after a canid consumes a rodent infected with cysts. Larvae within the cyst develop into adult tapeworms in the intestinal tract of the canid. Eggs may be passed in the feces of the canid approximately 28 days later.

This parasite poses a serious public health problem because of the possibility for human involvement in the life cycle. If eggs shed by an infected canid are accidentally ingested, a highly pathogenic condition (Alveolar Hydatid Disease) results from development of the cyst stage in humans.

The original geographic distribution of E. multilocularis was primarily confined to northern areas of North America. Current evidence indicates migration of the parasite well into the continental United States.3,4

Domestic dogs living in E. multilocularis endemic areas that roam freely with the opportunity to catch wild rodents are at risk of infection. Pet owners should be advised on how to minimize this risk. Proper restraint of dogs should be encouraged, along with regular treatment with Drontal Plus Taste Tabs Tablets, following the dosing schedule aforementioned and precautions indicated below.

Additional information on the life cycle and epidemiology of this parasite is available in veterinary parasitology texts.5,6

SPL UNCLASSIFIED SECTION

DIAGNOSIS: Diagnosis of E. multilocularis in canids is difficult. The adult tapeworm produces no clinical signs of infection. Tapeworm segments (proglottids) are usually not observed in the feces. E. multilocularis eggs, observed using microscopic fecal examination procedures, are similar in appearance to those of common species such as Taenia pisiformis.

Assistance in the diagnosis of E. multilocularis may be available from a state veterinary diagnostic laboratory. Additional information regarding areas where E. multilocularis is suspected or has been confirmed may be obtained from area veterinary schools or the Centers for Disease Control in Atlanta, GA.

SPL UNCLASSIFIED SECTION

TREATMENT: Dogs infected with E. multilocularis should be treated to prevent exposure of humans to infective eggs and to break the parasite's life cycle.

The dosage of Drontal Plus Taste Tabs Tablets for removal of E. multilocularis is the same as that indicated for the removal of the other tapeworm species listed on the label. Laboratory efficacy studies conducted with Drontal Plus tablets have demonstrated the recommended dosage is 100% effective.

Under condition of continual exposure to wild rodents, retreatment of the dog at 21-26 day intervals is recommended to prevent the shedding of infectious eggs.

SPL UNCLASSIFIED SECTION

EFFICACY: A total of 176 dogs and puppies with naturally acquired or experimental parasite infections were included in 4 well-controlled laboratory studies to establish the efficacy of Drontal Plus Anthelmintic Tablets. In addition, 103 dogs and puppies were included in clinical field studies conducted in 5 veterinary clinics at different geographic locations throughout the United States to further evaluate safety and efficacy. These studies included dogs of various sizes, ages and breeds. Data from these studies demonstrated Drontal Plus Anthelmintic Tablets are safe and efficacious for the removal of the parasite species indicated on the label when used as directed.

Results obtained in the laboratory and clinical studies indicate small numbers of hookworm or roundworm eggs may be passed in the feces for up to 7 days after treatment although the worms themselves were eliminated. A follow-up fecal examination should be conducted 2 to 4 weeks after treatment to determine the need for retreatment.

SPL UNCLASSIFIED SECTION

Palatability: Palatability studies with Drontal Plus Taste Tabs Tablets were conducted at 3 different veterinary clinics in the United States. These studies included a total of 151 dogs (65 males / 86 females) representing 34 different breeds with body weights ranging from 3.8 - 190 lbs. The tablets were offered free-choice to the dogs by their owners and over 89% of the dogs willingly consumed the tablets.

ADVERSE REACTIONS:

ADVERSE REACTIONS SECTION

None of the 103 dogs treated with Drontal Plus Anthelmintic Tablets in the clinical field studies exhibited drug-related side effects. Of the 40 dogs treated with Drontal Plus Taste Tabs Tablets in laboratory studies, two dogs exhibited vomiting, one puppy exhibited bloody/mucoid stool and one puppy exhibited watery/profuse stool.

CONTACT INFORMATION:

SPL UNCLASSIFIED SECTION

For product questions, to report adverse reactions, or for a copy of the Safety Data Sheet (SDS), call Elanco Product & Veterinary Support at 888-545-5973. For additional information about reporting adverse drug experiences for animal drugs, contact FDA at 1-888-FDA-VETS or www.fda.gov/reportanimalae.

ANIMAL SAFETY:

ANIMAL PHARMACOLOGY & OR TOXICOLOGY SECTION

Controlled safety evaluations have been conducted in dogs with Drontal Plus (praziquantel/pyrantel pamoate/febantel) Anthelmintic Tablets. Dogs receiving up to 5 times the label dosage (35 mg praziquantel, 35 mg pyrantel pamoate and 179 mg febantel per kg of body weight) for 3 consecutive days (3 times the label duration) showed clinical signs of vomition and non-formed stools. One dog receiving a 3 times labeled dose had elevated SGPT, SGOT, CPK and GGT readings (outside of normal range) at 6 days post-treatment. No additional findings were noted in hematology/clinical chemistry parameters nor were there any treatment-related histological lesions. Vomition was the only side effect observed when dogs received a single treatment of 61 mg praziquantel, 61 mg pyrantel pamoate and 305 mg febantel/kg with one dog having an elevated SGPT reading (outside of normal range) at 24 hours post-treatment which had returned to normal by 7 days.

STORAGE CONDITIONS:

STORAGE AND HANDLING SECTION

Drontal Plus Taste Tabs Tablets should be stored at or below 77 °F (25 °C).

Un-blistered whole or partial tablets should be stored in a tightly sealed container.

HOW SUPPLIED:

HOW SUPPLIED SECTION

Drontal Plus Taste Tabs Tablets are available in three tablet sizes:

40 tabs/box for Puppies and Small Dogs

40 tabs/box for Medium Sized Dogs

30 tabs /box for Large Dogs

REFERENCES:

REFERENCES SECTION

  1. Andrews P. 1976. Pharmacokinetic Studies with DRONCIT in Animals Using a Biological Assay. Veterinary Medical Review. 2:154-165.
  2. Campbell WC. 1986. The Chemotherapy of Parasitic Infections. J. Parasit. 72(1):45-61.
  3. Hildreth MB Johnson MD and Kazacos KR. 1991. A Zoonosis of Increasing Concern in the United States. Compendium for Cont. Ed. 13(5): 727-740.
  4. Lieby PD Carney WP and Woods CE. 1970. Studies on Sylvatic Echinococcosis, III. Host Occurrence and Geographic Distribution of Echinococcus multilocularis in the North Central United States. J. Parasit. 56(6): 1141-1150.
  5. Georgi JR and Georgi ME. 1990. Parasitology for Veterinarians. W.B. Saunders Co. 118-138.
  6. Soulsby EJL. 1982. Helminths, Arthropods and Protozoa of Domesticated Animals. 7th Edition. Lea & Febiger. 118-138.
  7. Craig PS and McPharson CNL. 1988. Sodium Hypochlorite as an Ovicide for Echinococcus. Ann Trop Med. and Parasit. 82(2): 211-213.
  8. Freedom of Information Summary (FOI) NADA 133-953 Vercom Paste (febantel and praziquantel).

Patent information at
www.elancopatents.com
November 2025
PA104396X

Drontal, Taste Tabs, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates.

© 2025 Elanco or its affiliates

Manufactured for:
Elanco US Inc
Indianapolis, IN 46221 U.S.A.
Approved by FDA under NADA # 141-007

Elanco™

Principal Display Panel - Puppies and Small Dogs (2-25 lbs.) Box Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

40 Taste Tabs (4 strips of 10 Tablets)

Taste TabsTM
DrontalTM Plus
(praziquantel/pyrantel pamoate/febantel)

Broad Spectrum Chewable Anthelmintic
For Puppies and Small Dogs (2-25 lbs.)

CAUTION: Federal law restricts this drug to
use by or on the order of a licensed veterinarian.

Elanco™

Manufactured for:
Elanco US Inc.
Indianapolis, IN 46221 U.S.A.
Approved by FDA under NADA # 141-007

Each Drontal Plus Taste Tabs Tablet contains:
22.7 mg praziquantel, 22.7 mg pyrantel base
as pyrantel pamoate, and 113.4 mg febantel

WARNING: KEEP OUT OF REACH OF CHILDREN

Principal Display Panel - Puppies and Small Dogs (2-25 lbs.) Box Label
Principal Display Panel - Puppies and Small Dogs (2-25 lbs.) Box Label

Principal Display Panel - Medium Sized Dogs (26-60 lbs.) Box Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

40 Taste Tabs (4 strips of 10 Tablets)

Taste TabsTM
DrontalTM Plus
(praziquantel/pyrantel pamoate/febantel)

Broad Spectrum Chewable Anthelmintic
For Medium Sized Dogs (26-60 lbs.)

CAUTION: Federal law restricts this drug to
use by or on the order of a licensed veterinarian.

Elanco™

Manufactured for:
Elanco US Inc.
Indianapolis, IN 46221 U.S.A
Approved by FDA under NADA # 141-007

Each Drontal Plus Taste Tabs Tablet contains:
68.0 mg praziquantel, 68.0 mg pyrantel base
as pyrantel pamoate, and 340.2 mg febantel

WARNING: KEEP OUT OF REACH OF CHILDREN

Principal Display Panel - Medium Sized Dogs (26-60 lbs.) Box Label
Principal Display Panel - Medium Sized Dogs (26-60 lbs.) Box Label

Principal Display Panel - Large Dogs (45 lbs. and greater) Box Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

30 Taste Tabs (3 strips of 10 Tablets)

Taste TabsTM
DrontalTM Plus
(praziquantel/pyrantel pamoate/febantel)

Broad Spectrum Chewable Anthelmintic
For Large Dogs (45 lbs. and greater)

CAUTION: Federal law restricts this drug to use by
or on the order of a licensed veterinarian.

Elanco™

Manufactured for:
Elanco US Inc
Indianapolis, IN 46221 U.S.A.
Approved by FDA under NADA # 141-007

Each Drontal Plus Taste Tabs Tablet contains:
136.0 mg praziquantel, 136.0 mg pyrantel base
as pyrantel pamoate, and 680.4 mg febantel

WARNING: KEEP OUT OF REACH OF CHILDREN

Principal Display Panel - Large Dogs (45 lbs. and greater) Box Label
Principal Display Panel - Large Dogs (45 lbs. and greater) Box Label

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
892101Drontal Plus for large dogs (45 lbs. and greater) Chewable TabletPSN8
892337Drontal Plus Taste Tabs for medium sized dogs (26-60 lbs) Chewable TabletPSN8
892331Drontal Plus Taste Tabs for puppies and small dogs (2-25 lbs) Chewable TabletPSN8
892099praziquantel 136 MG / pyrantel 136 MG / febantel 680 MG Chewable TabletPSN8
892330praziquantel 22.7 MG / pyrantel 22.7 MG / febantel 113 MG Chewable TabletPSN8
892336praziquantel 68 MG / pyrantel 68 MG / febantel 340 MG Chewable TabletPSN8
892331febantel 113 MG / praziquantel 22.7 MG / pyrantel 22.7 MG Chewable Tablet [Drontal Plus]SBD8
892337febantel 340 MG / praziquantel 68 MG / pyrantel 68 MG Chewable Tablet [Drontal Plus]SBD8
892101febantel 680 MG / praziquantel 136 MG / pyrantel 136 MG Chewable Tablet [Drontal Plus]SBD8
892330febantel 113 MG / praziquantel 22.7 MG / pyrantel 22.7 MG Chewable TabletSCD8
892336febantel 340 MG / praziquantel 68 MG / pyrantel 68 MG Chewable TabletSCD8
892099febantel 680 MG / praziquantel 136 MG / pyrantel 136 MG Chewable TabletSCD8
892101Drontal Plus for large dogs (45 lbs. and greater) Chewable TabletSY8
892331Drontal Plus Taste Tabs (febantel 113.4 MG / praziquantel 22.7 MG / pyrantel 22.7 MG) Chewable TabletSY8
892337Drontal Plus Taste Tabs (febantel 340.2 MG / praziquantel 68 MG / pyrantel 68 MG) Chewable TabletSY8
892101Drontal Plus Taste Tabs (febantel 680.4 MG / praziquantel 136 MG / pyrantel 136 MG) Chewable TabletSY8
892337Drontal Plus Taste Tabs for medium sized dogs (26-60 lbs) Chewable TabletSY8
892331Drontal Plus Taste Tabs for puppies and small dogs (2-25 lbs) Chewable TabletSY8

Product Linked Resources#

Resource, Code type, Value table
ResourceCode typeValueEquivalent identifiersSource image
Data codeData MatrixSH104396Xdro0b-0001-02.jpg
Data codeData MatrixSH104397Xdro0b-0001-03.jpg
Data codeData MatrixSH104398Xdro0b-0001-04.jpg

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
8cabd598-669e-43ab-9753-4aec00a484cbProduct name120180125

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
58198-0067-1DRONTAL PLUS TASTE TABS10 in 1 BLISTER PACKTABLET, CHEWABLE108
58198-0067-1DRONTAL PLUS TASTE TABS3 in 1 BOXTABLET, CHEWABLE38
58198-0068-1DRONTAL PLUS TASTE TABS4 in 1 BOXTABLET, CHEWABLE48
58198-0068-1DRONTAL PLUS TASTE TABS10 in 1 BLISTER PACKTABLET, CHEWABLE108
58198-0069-1DRONTAL PLUS TASTE TABS10 in 1 BLISTER PACKTABLET, CHEWABLE108
58198-0069-1DRONTAL PLUS TASTE TABS4 in 1 BOXTABLET, CHEWABLE48

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 6 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
58198-006858198-0068-1
58198-006958198-0069-1
58198-006758198-0067-1

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 9 matching rows.

Source Document#

Source XML

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 2 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
PRAZIQUANTELPRAZIQUANTELPar Health USA, LLC16f2b9c4-a260-4a31-bd52-e5945913246c2026-08-12Warnings, Adverse reactionsName fallback
generic name: PRAZIQUANTEL
BiltricidePRAZIQUANTELBayer HealthCare Pharmaceuticals Inc.34ce1cdd-648e-4f1e-8512-bf3d4cc22eb92026-03-02Warnings, Adverse reactionsName fallback
generic name: PRAZIQUANTEL

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.